<DOC>
	<DOCNO>NCT00497536</DOCNO>
	<brief_summary>The primary objective study compare SSPIAsp CSII give one bolus per hour compare multiple bolus per hour . The secondary objective compare SSPIAsp continuous subcutaneous insulin infusion ( CSII ) versus continuous intravenous insulin infusion ( CIII ) .</brief_summary>
	<brief_title>Pharmacokinetics IAsp Following CSII Patients With T1DM</brief_title>
	<detailed_description>Rapid act insulin , like insulin aspart , administer CSII . The insulin administer basal rate additional insulin administration pump relate mealtime . Insulin physiologically secrete pulsate manner pancreatic β-cells period 5-10 minute , responsible plasma insulin oscillation similar frequency . The oscillatory pattern believe optimize control mechanisms insulin enhance action metabolism .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus ( T1DM ) Insulin pump user ' ≥ 48 hour , 24 h dose &lt; 80 U Insulin dose ≥ 0,4 IE/kg/24hours 18 year &lt; age &lt; 50 year Time since diagnosis T1DM ≥ 5 year HbA1c ≤ 8,5 % Safe anticonceptive fertile woman Being able understand read Danish Dysregulation endocrine disorder type 1 diabetes mellitus Severe dysregulation diabetes mellitus Other severe adverse disease Pregnancy , plan pregnancy , nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Continuous Subcutaneous Insulin Infusion ( CSII )</keyword>
</DOC>